To evaluate whether anti-PD-1 treatment was affecting the phenotype and functionality of the tumor-associated T cells, we used flow cytometry to assess the co-expression of co-inhibitory markers, PD-1 and Lag-3, by the CD8+ T cells (Figure 5A) as well as PD-1 single positive expression by the CD8+ and CD4+ T cells (Supplemental Figures 6B,C). The gene discussed is CD4; the disease is neoplasm.